Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed

Hidetoshi Hayashi, Isamu Okamoto, Yasuko Ichikawa, Masaki Miyazaki, Hiroshige Yoshioka, Kei Kunimasa, Kazuhiko Nakagawa

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

Combination chemotherapy with cisplatin and pemetrexed is the most active first-line regimen for malignant pleural mesothelioma (MPM). However, no drugs have been approved for second-line treatment of MPM, with effective regimens remaining to be identified for patients in relapse. We have now evaluated the combination of cisplatin and pemetrexed for retreatment of patients with recurrent MPM. Four men with MPM, all of whom received initial treatment with cisplatin and pemetrexed, underwent retreatment with this drug combination. Two of the patients achieved an objective response to the first-line chemotherapy with no evidence of disease progression for 6.4 or 11.4 months, respectively. The other two patients had stable disease with a duration of 7.8 or 5.0 months, respectively. The two patients who showed an objective response to first-line chemotherapy showed a partial response to retreatment, with a time to progression of 5.0 or 8.2 months, whereas the other two patients had progressive disease with a time to progression of 1.0 or 1.4 months, respectively. Retreatment with cisplatin plus pemetrexed was generally well tolerated. Retreatment with cisplatin and pemetrexed is a potential therapeutic option for certain patients with recurrent epithelioid MPM, possibly including those who show tumor regression with a time to progression of 6 months or more after the initial chemotherapy. Further studies are warranted to evaluate the efficacy of such retreatment and to clarify the criteria for patient selection.

Original languageEnglish
Pages (from-to)497-499
Number of pages3
JournalInternational Journal of Clinical Oncology
Volume15
Issue number5
DOIs
Publication statusPublished - Oct 2010
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed'. Together they form a unique fingerprint.

Cite this